rss
Br J Ophthalmol 2004;88:842 doi:10.1136/bjo.2003.036954
  • Letter

Peripheral visual field loss following treatment with etanercept

  1. L J Clifford,
  2. J D Rossiter
  1. Queen Alexandra Hospital, Portsmouth, UK
  1. Correspondence to: MrJonathan D Rossiter, Moorfields Eye Hospital City Road, London, EC1V 2PD, UK; jrossiterdoctors.org.uk
  • Accepted 28 October 2003

Etanercept is a relatively new anti-tumour necrosis factor α (TNF-α) therapy for inflammatory arthritides. Although there may be an association with uveitis,1 there have been no reports of patients experiencing visual disturbance.2 We present a case of a patient who developed symptomatic bilateral peripheral visual field loss shortly after initiation of treatment with etanercept.

Case report

A 59 year old woman was referred complaining of bilateral, sequential peripheral visual field disturbance, which developed during a course of etanercept therapy for rheumatoid arthritis. Initially she noticed a left upper temporal field defect occurring the day after receiving the first injection of etanercept. Following the second injection she became aware of …

[Full text of this article]

This Article

  1. Extract
  2. Full text
  3. PDF

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.